Evidence map›Paper›PMID 39652422›Full record

ArticleThe Journal of experimental medicine2025

A STAG2-PAXIP1/PAGR1 axis suppresses lung tumorigenesis.

Emily L Ashkin, Yuning J Tang, Haiqing Xu, King L Hung, Julia A Belk, Hongchen Cai, Steven S Lopez, Deniz Nesli Dolcen, Jess D Hebert, Rui Li and 8 more

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Emily L AshkinCancer Biology Program, Stanford University School of Medicine , Stanford, CA, USA.ORCID 0000-0001-7363-7860
Yuning J Tang *Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0009-0006-7037-2901
Haiqing Xu *Department of Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-9124-3192
King L HungCancer Biology Program, Stanford University School of Medicine , Stanford, CA, USA.ORCID 0000-0002-3662-4662
Julia A BelkCenter for Personal Dynamic Regulomes, Stanford University School of Medicine , Stanford, CA, USA.ORCID 0000-0003-4724-6158
Hongchen CaiDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-5921-5773
Steven S LopezDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0009-0008-0926-0016
Deniz Nesli DolcenDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2441-7313
Jess D HebertDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-8778-5941
Rui LiCenter for Personal Dynamic Regulomes, Stanford University School of Medicine , Stanford, CA, USA.ORCID 0000-0003-0056-7210
Paloma A RuizDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-6208-5087
Tula KealGene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0009-0007-7760-9315
Laura AndrejkaDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-2202-5626
Howard Y ChangCenter for Personal Dynamic Regulomes, Stanford University School of Medicine , Stanford, CA, USA.ORCID 0000-0002-9459-4393
Dmitri A PetrovCancer Biology Program, Stanford University School of Medicine , Stanford, CA, USA.ORCID 0000-0002-3664-9130
Jesse R DixonGene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-6273-2181
Zhichao XuGene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-0532-1706
Monte M WinslowCancer Biology Program, Stanford University School of Medicine , Stanford, CA, USA.ORCID 0000-0002-5730-9573

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI MICHAEL KENNEY · 2007 to 2026
$71.4M
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
UC San Diego Genetics Training ProgramT32GM145427 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRUCE A HAMILTON · 2022 to 2026
$2.6M
Unraveling mechanisms of tumor suppression in lung cancerR01CA234349 · NCI · STANFORD UNIVERSITY · PI PETROV, DMITRI, WINSLOW, MONTE MEIER · 2019 to 2023
$2.4M
(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivoR01CA231253 · NCI · STANFORD UNIVERSITY · PI PETROV, DMITRI, WINSLOW, MONTE MEIER · 2018 to 2022
$2.3M
Biological and cancer-associated role of epitranscriptomic gene expression regulationK00CA245784 · NCI · STANFORD UNIVERSITY · PI Deniz Nesli Dolcen · 2023 to 2026
$386k
Regulation and retention of extrachromosomal oncogene amplifications in cancerF99CA274692 · NCI · STANFORD UNIVERSITY · PI HUNG, KING L. · 2022 to 2023
$82k
Chromatin and immune regulation of tumor growth and progressionF99CA284289 · NCI · STANFORD UNIVERSITY · PI ASHKIN, EMILY LORIN · 2023 to 2023
$49k
American Cancer Society PF-21-112-01-MMCanadian Institute of Health Research MFE-176568Howard Hughes Medical Institute GT14928National Science Foundation Graduate Research Fellowship Program DGE-2146755NCI NIH HHS F99 CA274692NCI NIH HHS F99 CA284289NCI NIH HHS F99CA284289NCI NIH HHS K00 CA245784NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA231253NCI NIH HHS R01 CA234349NCI NIH HHS T32 CA009302NIGMS NIH HHS T32 GM145427NIH HHS R01-CA231253Stanford UniversityTobacco-Related Disease Research Program 28FT-0019
6 · The paper itself

Abstract

The cohesin complex is a critical regulator of gene expression. STAG2 is the most frequently mutated cohesin subunit across several cancer types and is a key tumor suppressor in lung cancer. Here, we coupled somatic CRISPR-Cas9 genome editing and tumor barcoding with an autochthonous oncogenic KRAS-driven lung cancer model and showed that STAG2 is uniquely tumor-suppressive among all core and auxiliary cohesin components. The heterodimeric complex components PAXIP1 and PAGR1 have highly correlated effects with STAG2 in human lung cancer cell lines, are tumor suppressors in vivo, and are epistatic to STAG2 in oncogenic KRAS-driven lung tumorigenesis in vivo. STAG2 inactivation elicits changes in gene expression, chromatin accessibility, and 3D genome conformation that impact the cancer cell state. Gene expression and chromatin accessibility similarities between STAG2- and PAXIP1-deficient neoplastic cells further relate STAG2-cohesin to PAXIP1/PAGR1. These findings reveal a STAG2-PAXIP1/PAGR1 tumor-suppressive axis and uncover novel PAXIP1-dependent and PAXIP1-independent STAG2-cohesin-mediated mechanisms of lung tumor suppression.

Indexed as

CarcinogenesisCell Cycle ProteinsLung NeoplasmsAnimalsAntigens, NuclearCell Line, TumorCohesinsCRISPR-Cas SystemsGene Expression Regulation, NeoplasticHumansMiceTumor Suppressor ProteinsAntigens, NuclearCell Cycle ProteinsCohesinsSTAG2 protein, humanTumor Suppressor Proteins

Identifiers

PMID39652422
PMCPMC11627241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.